DAB
- Founded in: 2012
- Number of employees: 5
- Country: The Netherlands
- Investors: Delft University of Technology and Private investor
- Market: DAB enables market introduction of biotech production processes or opens up new and larger market opportunities. DAB's intensifying fermentation and integrated separation technology helps industrial biotechnology industries to boost their productivities. Markets that benefit produce a product that can phase separate, or can be extracted by liquid extraction like oleochemicals, terpenes or hydrocarbons. The best market fit of DAB's technology is a process that benefits from process intensification. Typically it concerns a fermentation process that is product inhibited or has a complex down stream processing.
- Website: http://delftab.com
Which input provides your business model/core technology towards a bio-based economy?
DAB enables the biobased economy. Biobased initiatives often struggle with setting their product price competitive in the market. DAB's Fermentation Accelaration and Separation Technology (FAST) is the boost solution to common issuess In Industrial Biotechnology like low productivity by product inhibition. It can help to reduce investment costs and high separation costs. By combining fermentation and separation in one continuous in-situ removal production system, we reduce operational costs up to 50%. Our business model is to team up with CMO's for specialty chemicals and to demonstrate our technology at scale in a dedicated consortium and then further out-licence the mature technology.
Which market/clients do you address and which short-term/long-term goals do you have?
To produce bio based products in a cost effective way, demands the best of every aspect of the production process: cheap and readily available feedstock, optimised strains, effective fermentation and separation technologies, healthy distribution agreements and more. Quite a lot for one single company, big or small. Therefore DAB believes that building consortia is the way to go forward for many parties in BioTech. DAB and its owners are actively looking to participate in and help build consortia. Our target is to expand our portfolio where the benefit of our FAST technology has already demonstrated and to retrofit a first production plant in 2020.
What makes your approach unique compared to other stakeholders in the field?
DAB’s solutions is to continuously produce and harvest product at the same time. This integrated solution avoids product inhibition, leads to a lower downtime and higher productivity than you would achieve in a fermentation vessel alone. DABs integrated design approach is unique and our solution is scalable a tailor-made integrated bioreactor or flexible add-on solution to an existing fermentation plant.
You can meet DAB in Toulouse at the START-UP VILLAGE @EFIB on 17-18 October.